findmyKOL
Clinical trialNCT04247542CompletedPhase 2Interventional

ACX-362E [Ibezapolstat] for Oral Treatment of Clostridioides Difficile Infection

SponsorAcurx Pharmaceuticals Inc.Enrollment53Clostridium Difficile Infection
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

29 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Acurx Site #118: Dr Janet Reiser

    Scottsdale, Arizona, United States

  • Acurx Site #115: Dr Neera Grover

    Apple Valley, California, United States

  • Acurx Site #125: Dr Karen Simon

    Camarillo, California, United States

  • Acurx Site #111: Dr Jatinder Pruthi

    Lancaster, California, United States

  • Acurx Site #131: Dr Michael Jardula

    Palm Springs, California, United States

  • Acurx Site #129: Dr Stuart Cohen

    Sacramento, California, United States

  • Acurx Site #105

    Doral, Florida, United States

  • Acurx Site #122: Dr Faride Ramos

    Doral, Florida, United States

  • Acurx Site #101: Dr Idalia Acosta

    Miami, Florida, United States

  • Acurx Site #108: Dr Idania Garcia del Sol

    Miami, Florida, United States

  • Acurx Site #116: Dr Erick Juarez

    Miami, Florida, United States

  • Acurx Site #119: Dr Jorge Paoli-Bruno

    Miami, Florida, United States

  • Acurx Site #124: Dr Yunior Silva-Barrero

    Miami, Florida, United States

  • Acurx Site #107: Dr Belkis Delgado

    Miami Springs, Florida, United States

  • Acurx Site #117: Dr Rafael Companioni

    Panama City, Florida, United States

  • Acurx Site #102: Dr Richard Nathan

    Idaho Falls, Idaho, United States

  • Acurx Site #123: Dr Harry Schrager

    Newton, Massachusetts, United States

  • Acurx Site #104: Dr Jeanmarie Houghton

    Worcester, Massachusetts, United States

  • Acurx Site #103: Dr John Pullman

    Butte, Montana, United States

  • Acurx Site #130: Dr Michael Digiovanna

    North Massapequa, New York, United States

  • Acurx Site #127: Dr Christopher Connolley

    Winston-Salem, North Carolina, United States

  • Acurx Site #126: Dr Andrew Pearson

    Myrtle Beach, South Carolina, United States

  • Acurx Site #114: Dr Eugene Ryan

    Chattanooga, Tennessee, United States

  • Acurx Site #121: Dr Ramesh Gowrappala

    Houston, Texas, United States

  • Acurx Site #120: Dr Vanna Gold

    Lampasas, Texas, United States

  • Acurx Site #113: Dr Jennifer Vincent

    Temple, Texas, United States

  • Acurx Site #110: Dr Val Hansen

    Bountiful, Utah, United States

  • Acurx Site #106: Dr Bezawit Tekola

    Fairfax, Virginia, United States

  • Acurx Site #109: Dr Robert Brennan

    Lynchburg, Virginia, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
6 Mar 2020
Primary completion
3 Oct 2023
Completion
15 Nov 2023
Last update posted
17 Jan 2025
Registered enrollment
53
Registry id
NCT04247542

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.